Good results from Stada Arz, despite challenging conditions

13 November 2014

German drugmaker Stada Arzneimittel (SAZ: GR) has posted financial results for the first nine months of 2014, showing that groups sales rose 4% to 1.48 billion euros ($1.84 billion), though down 1% adjusted for currency and portfolio effects. The company’s shares dipped 1.4% to 28.12 euros by late morning trading.

Reported earnings before interest, taxes, depreciation and amortization (EMITDA) rose by 10% to 293.6 million euros, with a similar rise in net income to 99.1 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Generics